{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40","upperLimit":"70","value":"53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"description":"Graft Versus Host Disease (GVHD) defined as grade 2 to 4 GVHD within first 100 days post transplant. Death or disease progression before diagnosis of GVHD were considered competing risks in the estimation of the incidence of acute GVHD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Busulfan starting dose of 32 mg/m\\^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3. Fludarabine dose of 40 mg/m\\^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan. Cyclophosphamide dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.","id":"OG000","title":"Busulfan + Fludarabine + Cyclophosphamide"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days post transplant","title":"Cumulative Incidence of Grade II to IV Acute GVHD","type":"PRIMARY","unitOfMeasure":"percentage of incidence"}